Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03852043
Other study ID # HIIT3_AFIS-UdeA
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 26, 2018
Est. completion date April 5, 2019

Study information

Verified date June 2019
Source Universidad de Antioquia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Overweight and obesity are a public health problem for society, reflected by an increase in its prevalence worldwide, being more frequent in women and related to low levels of self-esteem, accumulation of subcutaneous fat and internal organs, reduction of muscle mass (MM) and basal metabolic rate (BMR). Women are more predisposed to present weight gain because they are metabolically less efficient, have greater food intake, greater physical inactivity, and genetic factors. The different methods of physical training used for weight control are continuous training (CT) and the high-intensity interval training (HIIT). Both CT and HIIT have shown benefits without finding superiority of any of these methods. Nevertheless, there is a trend to the use HIIT programs, since they are more time-efficient and supports their use to induce physiological and metabolic adaptations over time, since this is a barrier to adherence to exercise programs. Overweight and obesity causes individual alterations in body composition and exercise leads to increase in MM, increase in caloric expenditure during the training session and increase in BMR due to the onset of muscle growth, secondary to an increase in the activity of the mitochondrial enzymes (greater mitochondrial biogenesis in the muscle), adaptations that could depend on the type of exercise, its intensity and the volume of it, but it is not clear due to the lack of evidence regarding this.

The primary objective of this study is to demonstrate that a HIIT program of short duration in a real-world setting has a standardized mean difference (SMD) higher than 0.84 in the improvement of self-esteem when comparing with a moderate-intensity continuous training (MICT) in women 18 to 44 years with overweight and obesity and low self-esteem, during eight weeks.

The secondary objective is to demonstrate that a low-volume HIIT in a real-world setting improves MM in 2% compared with MICT during a period of eight weeks in women 18 to 44 years.


Description:

Fifty women with low self-esteem will be randomly assigned to one of two training programs (MICT or HIIT) in a real-world setting. Both groups will perform three times a week for eight-weeks on alternate days.

The women in each group will perform three workouts per week for a period of eight weeks. The moderate-intensity continuous training group will perform a training session of 40 min duration at an intensity between 65 and 75% of your HRmax. Women assigned to the group HIIT will perform a training session of 22 minutes of duration by performing intervals of high intensity between 90 and 95 % of the HRmax for 30 seconds in duration and with a recovery of one minute training at moderate intensity is between 50 and 60 % of the HRmax, doing 15 loads of 30 seconds at high intensity, with 60 seconds of recovery between loads at moderate intensity. At the beginning of each training session, both groups will complete strength exercises mainly including large muscle groups (hip, knees, and ankles) with Theraband® (blue color ) for 3 sets of 15 repetitions.

All participants will be evaluated before initiating interventions and upon completion of the training program, after eight weeks, self-esteem will be assessed using the Rosenberg self-esteem scale, determination of anthropometric variables such as weight, height, waist circumference, arterial pressure, body composition by bioimpedance and the basal metabolic rate.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date April 5, 2019
Est. primary completion date January 28, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 44 Years
Eligibility Inclusion Criteria:

- Women 18 to 44 years old, overweighted (BMI = 25 kg / m2) who agree to participate by signing the informed consent, no more than 600 Met / physical activity min / wk (be quantified with the Global Physical Activity Questionnaire - GPAQ), and have less than 30 points on the self-esteem scale.

Exclusion Criteria:

- History of uncontrolled noncommunicable diseases (hypothyroidism, diabetes, asthma and high blood pressure, cardiac arrhythmias), motor disorders or sensitive to hinder the exercise, consumption of anticoagulants, medication altering heart rate (beta-blockers, calcium antagonists, bronchodilators), steroid use, abuse of psychoactive substances, personal history of surgical procedures in the last three months, depressive disorders; pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
High-intensity interval training
The intervals of high intensity are conducted between 90 and 95 % of heart rate maximum (HRmax) and resting between 50 and 60 % of the HRmax 15 loads of 30 seconds at high intensity, with 60 seconds of recovery at loads of moderate intensity.
Moderate-intensity continuous training
The continuous training will be carried out at an intensity between 65 and 75% of the HRmax.

Locations

Country Name City State
Colombia Universidad de Antioquia Medellín Antioquia

Sponsors (1)

Lead Sponsor Collaborator
Universidad de Antioquia

Country where clinical trial is conducted

Colombia, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in basal metabolic rate Basal metabolic rate will be quantified at the beginning of the study and at the end through a portable gas analyzer model K4b2 (Cosmed Inc, IL, USA), the test will be performed between 7:00 - 7:30 am, the participant must have a fast of at least five hours, and abstaining from consuming products with caffeine and alcoholic beverages 12 hours prior to the evaluation. During the test, the participant must remain seated at rest in an isolated room for 15 minutes. The measurement of the resting metabolic rate will be made during the next 10 minutes in the same position. The criteria to determine a valid measurement will be: the stay in a minimum of 10 minutes in steady state, determined by: discarding the first five minutes of the measurement, reaching a coefficient of variation =10% for VO2 and for VCO2 during the ten minutes remaining and a respiratory quotient between 0.7 to 1.0. Change from baseline and after 8 weeks
Primary Change in self-esteem Self-esteem will be measured by applying the Rosenberg self-esteem scale and according to the scores obtained, the individual will be classified as low self-esteem (<30 points) or normal (> 30 points). The internal consistency of the scale shows a Cronbach's alpha with values ranging between 0.83 and 0.88, and the reliability shows a test-retest correlation of 0.84. Therefore, there is high internal consistency and adequate temporal reliability. Supporting the validity (of construct and known groups) of the instrument. Change from baseline and after 8 weeks
Secondary Change in muscle mass Muscle Mass will be quantified through an Omron® HBF510 bioelectrical impedance scale, which has a capacity of 0 to 150 kg, an accuracy of 100 gr for the calculation of weight. Change from baseline and after 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1